Literature DB >> 31680243

Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined.

Xu-Feng Zhang1,2, Xiao-Ning Wu1, Diamantis I Tsilimigras2, George Poultsides3, Flavio Rocha4, Daniel E Abbott5, Ryan Fields6, Kamran Idrees7, Cliff Cho8, Shishir K Maithel9, Timothy M Pawlik2.   

Abstract

BACKGROUND: The current study sought to investigate the impact of tumor size and total number of LN examined (TNLE) on the incidence of lymph node metastasis (LNM) among patients with duodenal neuroendocrine tumor (dNET).
METHODS: Patients who underwent curative resection for dNETs between 1997-2016 were identified from 8 high-volume US centers. Risk factors associated with overall survival and LNM were identified and the optimal cut-off of TNLE relative to LNM was determined.
RESULTS: Among 162 patients who underwent resection of dNETs, median patient age was 59 (interquartile range [IQR], 51-68) years and median tumor size was 1.2 cm (IQR, 0.7-2.0 cm); a total of 101 (62.3%) patients underwent a concomitant LND at the time of surgery. Utilization of lymphadenectomy (LND) increased relative to tumor size (≤1 cm:52.2% vs 1-2 cm:61.4% vs >2 cm:93.8%; P < .05). Similarly, the incidence of LNM increased with dNET size (≤1 cm: 40.0% vs 1-2 cm:65.7% vs >2 cm:80.0%; P < .05). TNLE ≥ 8 had the highest discriminatory power relative to the incidence of LNM (area under the curve = 0.676). On multivariable analysis, while LNM was not associated with prognosis (hazard ratio [HR] = 0.9; 95% confidence intervals [95%CI], 0.4-2.3), G2/G3 tumor grade was (HR = 1.5; 95%CI, 1.0-2.1).
CONCLUSIONS: While the incidence of LNM directly correlated with tumor size, patients with dNETs ≤ 1 cm had a 40% incidence of LNM. Regional lymphadenectomy of a least 8 LN was needed to stage patients accurately.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ampulla; Duodenum; neuroendocrine tumor; prognosis; surgery

Mesh:

Year:  2019        PMID: 31680243     DOI: 10.1002/jso.25753

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

1.  Management of Duodenal Neuroendocrine Tumors: Surgical versus Endoscopic Mucosal Resection.

Authors:  Catherine G Tran; Scott K Sherman; Mohammed O Suraju; Apoorve Nayyar; Henning Gerke; Rami G El Abiad; Chandrikha Chandrasekharan; Po Hien Ear; Thomas M O'Dorisio; Joseph S Dillon; Andrew M Bellizzi; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-09-13       Impact factor: 5.344

Review 2.  How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Authors:  Francesca Fermi; Valentina Andreasi; Francesca Muffatti; Stefano Crippa; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Curr Oncol Rep       Date:  2022-01-25       Impact factor: 5.075

Review 3.  Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review.

Authors:  Shuzo Kohno
Journal:  Cancer Diagn Progn       Date:  2022-03-03

4.  Omission of Right Hemicolectomy May be Safe for Some Appendiceal Goblet Cell Adenocarcinomas: A Survival Analysis of the National Cancer Database.

Authors:  Stacy J Kowalsky; Ibrahim Nassour; Samer AlMasri; Alessandro Paniccia; Amer H Zureikat; Haroon A Choudry; James F Pingpank
Journal:  Ann Surg Oncol       Date:  2021-08-18       Impact factor: 5.344

5.  Development and Validation of Prognostic Nomograms for Patients with Duodenal Neuroendocrine Neoplasms.

Authors:  Shenghong Sun; Wei Wang; Chiyi He
Journal:  Med Sci Monit       Date:  2020-06-21

6.  Small, low-grade ampullary neuroendocrine tumor presenting with metastasis and multiple synchronous tumors in a patient with neurofibromatosis type 1: a case report with literature review.

Authors:  Kevin Xiao; Sharon Swierczynski; Gary Xiao
Journal:  J Surg Case Rep       Date:  2021-03-29

7.  Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.

Authors:  Alessandro Vanoli; Oneda Grami; Catherine Klersy; Anna Caterina Milanetto; Luca Albarello; Matteo Fassan; Claudio Luchini; Federica Grillo; Paola Spaggiari; Frediano Inzani; Silvia Uccella; Paola Parente; Gennaro Nappo; Paola Mattiolo; Massimo Milione; Andrea Pietrabissa; Lorenzo Cobianchi; Marco Schiavo Lena; Stefano Partelli; Antonio Di Sabatino; Christine Sempoux; Carlo Capella; Claudio Pasquali; Claudio Doglioni; Fausto Sessa; Aldo Scarpa; Guido Rindi; Marco Paulli; Alessandro Zerbi; Massimo Falconi; Enrico Solcia; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2022-05-13       Impact factor: 4.056

8.  Survival comparison between endoscopic and surgical resection for non-ampullary duodenal neuroendocrine tumor (1-2 cm).

Authors:  Jiebin Xie; Yuan Zhang; Ming He; Xu Liu; Pin Xie; Yueshan Pang
Journal:  Sci Rep       Date:  2022-09-12       Impact factor: 4.996

9.  Ampullary and Pancreatic Neuroendocrine Tumors: A Series of Cases and Review of the Literature.

Authors:  Venkata Vinod Kumar Matli; Gregory Wellman; Sathya Jaganmohan; Kirtan Koticha
Journal:  Cureus       Date:  2022-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.